A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/1000mg in Comparison to Each Component Gemigliptin 50mg and Metformin HCl Extended Release 1000mg Administered in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Gemigliptin/metformin (Primary) ; Gemigliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
- 07 May 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2014 New trial record